MRAS

Across TCGA pan-cancer cohorts, MRAS mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MRAS data layer compared with 20 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MRAS mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MRAS expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

UCEC, LUAD, and HNSC are the cancer types where MRAS mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	0.462	0.884	.017	8	view →
LUAD	OS	Quartile	III,IV	0.427	0.993	.040	3	view →
HNSC	DFS	Quartile	All	0.613	0.893	.033	2	view →
GBM	DFS	Quartile	All	0.935	0.679	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MRAS–UCEC (OS)

Open the UCEC breakdown →